Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[3H]vesamicol binding in human brain cholinergic deficiency disorders.

S J Kish1, L M Distefano, S Dozic

  • 1Human Brain Laboratory, Clarke Institute of Psychiatry, Toronto, Canada.

Neuroscience Letters
|September 18, 1990
PubMed
Summary

[3H]vesamicol binding in the brain remains largely unchanged in neurodegenerative diseases despite significant reductions in choline acetyltransferase (ChAT) activity. This suggests vesamicol binding sites may not solely indicate cholinergic nerve terminal density.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcome Analysis of Dual Plating in Management of Unstable Bicondylar Tibial Plateau Fracture - A Prospective Study.

Malaysian orthopaedic journal·2021
Same author

Acute Rejection of a Kidney Transplant in a Patient With Common Variable Immunodeficiency: A Case Report.

Transplantation proceedings·2017
Same author

The H1047R point mutation in p110 alpha changes the morphology of human colon HCT116 cancer cells.

Cell death discovery·2016
Same author

Bcl-2 together with PI3K p110α regulates cell morphology and cell migration.

Cell death & disease·2015
Same author

Successful autotransplantation of a mature mesiodens to replace a traumatized maxillary central incisor.

International endodontic journal·2014
Same author

Identification of FUS p.R377W in essential tremor.

European journal of neurology·2013

Area of Science:

  • Neuroscience
  • Neurochemistry
  • Neuropathology

Background:

  • Cholinergic system dysfunction is implicated in several neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease with dementia, olivopontocerebellar atrophy, and Down's syndrome.
  • Choline acetyltransferase (ChAT) is a key enzyme for acetylcholine synthesis and a marker for cholinergic nerve terminals.
  • [3H]vesamicol is a specific blocker of the vesicular acetylcholine transporter, used to label cholinergic nerve terminals.

Purpose of the Study:

  • To investigate the relationship between [3H]vesamicol binding and ChAT activity in the frontal cortex and amygdala of patients with disorders characterized by cholinergic deficits.
  • To determine if [3H]vesamicol binding accurately reflects the loss of cholinergic nerve terminals in these conditions.

Main Methods:

Related Experiment Videos

  • Radioligand binding assays using [3H]vesamicol were performed on autopsied brain tissue (frontal cortex and amygdala) from patients with Alzheimer's disease, Parkinson's disease with dementia, olivopontocerebellar atrophy, Down's syndrome, and control subjects.
  • Choline acetyltransferase (ChAT) activity was measured in the same tissue samples.

Main Results:

  • A significant reduction in ChAT activity (approximately 60% in frontal cortex, and 80% or more in amygdala) was observed in the patient groups compared to controls.
  • Despite the marked reduction in ChAT activity, [3H]vesamicol binding density was, on average, normal or only slightly reduced in the patient groups.
  • This discrepancy was observed across all four studied disorders.

Conclusions:

  • [3H]vesamicol binding in the human brain may not be exclusively localized to cholinergic nerve endings.
  • Alternatively, a significant portion of vesamicol binding sites may persist on cholinergic nerve terminals even after substantial loss of ChAT activity in cholinergic deficiency syndromes.
  • These findings challenge the assumption that [3H]vesamicol binding directly correlates with cholinergic nerve terminal density in pathological conditions.